The Frequency of Ras Mutations in Cancer

Overview

Journal Cancer Res

Specialty Oncology

Date 2020 Mar 27

PMID 32209560

Citations 432

Authors

Ian A Prior

Fiona E Hood

James L Hartley

Affiliations

Soon will be listed here.

Abstract

Ras is frequently mutated in cancer, however, there is a lack of consensus in the literature regarding the cancer mutation frequency of Ras, with quoted values varying from 10%-30%. This variability is at least in part due to the selective aggregation of data from different databases and the dominant influence of particular cancer types and particular Ras isoforms within these datasets. To provide a more definitive figure for Ras mutation frequency in cancer, we cross-referenced the data in all major publicly accessible cancer mutation databases to determine reliable mutation frequency values for each Ras isoform in all major cancer types. These percentages were then applied to current U.S. cancer incidence statistics to estimate the number of new patients each year that have Ras-mutant cancers. We find that approximately 19% of patients with cancer harbor Ras mutations, equivalent to approximately 3.4 million new cases per year worldwide. We discuss the Ras isoform and mutation-specific trends evident within the datasets that are relevant to current Ras-targeted therapies.

Citing Articles

KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of Immunotherapy.

Uniyal P, Kashyap V, Behl T, Parashar D, Rawat R Cancers (Basel). 2025; 17(5).

PMID: 40075634 PMC: 11899378. DOI: 10.3390/cancers17050785.

Revealing Functional Hotspots: Temperature-Dependent Crystallography of K-RAS Highlights Allosteric and Druggable Sites.

Deck S, Xu M, Milano S, Cerione R bioRxiv. 2025; .

PMID: 40060414 PMC: 11888411. DOI: 10.1101/2025.02.27.639303.

Oncogenic RAS induces a distinctive form of non-canonical autophagy mediated by the P38-ULK1-PI4KB axis.

Wang X, Li S, Lin S, Han Y, Zhan T, Huang Z Cell Res. 2025; .

PMID: 40055523 DOI: 10.1038/s41422-025-01085-9.

Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population.

Arun A, Liarakos D, Mendiratta G, Kim J, Goshua G, Olson P Pharmacogenomics J. 2025; 25(1-2):5.

PMID: 40044654 DOI: 10.1038/s41397-025-00364-3.

Recent Anti-KRAS Therapies: A "Possible Impossibility" for Pancreatic Ductal Adenocarcinoma.

Sobhani N, Pittacolo M, DAngelo A, Marchegiani G Cancers (Basel). 2025; 17(4).

PMID: 40002297 PMC: 11853620. DOI: 10.3390/cancers17040704.

References

Brandt R, Sell T, Luthen M, Uhlitz F, Klinger B, Riemer P . Cell type-dependent differential activation of ERK by oncogenic KRAS in colon cancer and intestinal epithelium. Nat Commun. 2019; 10(1):2919. PMC: 6606648. DOI: 10.1038/s41467-019-10954-y. View

Tate J, Bamford S, Jubb H, Sondka Z, Beare D, Bindal N . COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2018; 47(D1):D941-D947. PMC: 6323903. DOI: 10.1093/nar/gky1015. View

Suh J, Johnson A, Albacker L, Wang K, Chmielecki J, Frampton G . Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials. Oncologist. 2016; 21(6):684-91. PMC: 4912374. DOI: 10.1634/theoncologist.2016-0030. View

Xiong Y, Lu J, Hunter J, Li L, Scott D, Choi H . Covalent Guanosine Mimetic Inhibitors of G12C KRAS. ACS Med Chem Lett. 2017; 8(1):61-66. PMC: 5238463. DOI: 10.1021/acsmedchemlett.6b00373. View

Burd C, Liu W, Huynh M, Waqas M, Gillahan J, Clark K . Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. Cancer Discov. 2014; 4(12):1418-29. PMC: 4258185. DOI: 10.1158/2159-8290.CD-14-0729. View

Johnson C, Lin Y, Reid D, Parker J, Pavlopoulos S, Dischinger P . Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D. Cell Rep. 2019; 28(6):1538-1550.e7. PMC: 6709685. DOI: 10.1016/j.celrep.2019.07.026. View

Buhrman G, Senthil Kumar V, Cirit M, Haugh J, Mattos C . Allosteric modulation of Ras-GTP is linked to signal transduction through RAF kinase. J Biol Chem. 2010; 286(5):3323-31. PMC: 3030338. DOI: 10.1074/jbc.M110.193854. View

Sack L, Davoli T, Li M, Li Y, Xu Q, Naxerova K . Profound Tissue Specificity in Proliferation Control Underlies Cancer Drivers and Aneuploidy Patterns. Cell. 2018; 173(2):499-514.e23. PMC: 6643283. DOI: 10.1016/j.cell.2018.02.037. View

Novotny C, Hamilton G, McCormick F, Shokat K . Farnesyltransferase-Mediated Delivery of a Covalent Inhibitor Overcomes Alternative Prenylation to Mislocalize K-Ras. ACS Chem Biol. 2017; 12(7):1956-1962. PMC: 6070134. DOI: 10.1021/acschembio.7b00374. View

10.

Drosten M, Simon-Carrasco L, Hernandez-Porras I, Lechuga C, Blasco M, Jacob H . H-Ras and K-Ras Oncoproteins Induce Different Tumor Spectra When Driven by the Same Regulatory Sequences. Cancer Res. 2016; 77(3):707-718. DOI: 10.1158/0008-5472.CAN-16-2925. View

11.

Hoadley K, Yau C, Hinoue T, Wolf D, Lazar A, Drill E . Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell. 2018; 173(2):291-304.e6. PMC: 5957518. DOI: 10.1016/j.cell.2018.03.022. View

12.

Johnson C, Reid D, Parker J, Salter S, Knihtila R, Kuzmic P . The small GTPases K-Ras, N-Ras, and H-Ras have distinct biochemical properties determined by allosteric effects. J Biol Chem. 2017; 292(31):12981-12993. PMC: 5546037. DOI: 10.1074/jbc.M117.778886. View

13.

Serrano M, Lin A, McCurrach M, Beach D, Lowe S . Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997; 88(5):593-602. DOI: 10.1016/s0092-8674(00)81902-9. View

14.

Bournet B, Muscari F, Buscail C, Assenat E, Barthet M, Hammel P . KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016; 7:e157. PMC: 4822095. DOI: 10.1038/ctg.2016.18. View

15.

Hunter J, Manandhar A, Carrasco M, Gurbani D, Gondi S, Westover K . Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. Mol Cancer Res. 2015; 13(9):1325-35. DOI: 10.1158/1541-7786.MCR-15-0203. View

16.

Blons H, Emile J, le Malicot K, Julie C, Zaanan A, Tabernero J . Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. Ann Oncol. 2014; 25(12):2378-2385. DOI: 10.1093/annonc/mdu464. View

17.

Hammond D, Mageean C, Rusilowicz E, Wickenden J, Clague M, Prior I . Differential reprogramming of isogenic colorectal cancer cells by distinct activating KRAS mutations. J Proteome Res. 2015; 14(3):1535-46. PMC: 4356034. DOI: 10.1021/pr501191a. View

18.

Terrell E, Durrant D, Ritt D, Sealover N, Sheffels E, Spencer-Smith R . Distinct Binding Preferences between Ras and Raf Family Members and the Impact on Oncogenic Ras Signaling. Mol Cell. 2019; 76(6):872-884.e5. PMC: 7001861. DOI: 10.1016/j.molcel.2019.09.004. View

19.

Santra T, Herrero A, Rodriguez J, von Kriegsheim A, Iglesias-Martinez L, Schwarzl T . An Integrated Global Analysis of Compartmentalized HRAS Signaling. Cell Rep. 2019; 26(11):3100-3115.e7. DOI: 10.1016/j.celrep.2019.02.038. View

20.

Kleeff J, Korc M, Apte M, La Vecchia C, Johnson C, Biankin A . Pancreatic cancer. Nat Rev Dis Primers. 2016; 2:16022. DOI: 10.1038/nrdp.2016.22. View